SymBio Pharmaceuticals Limited

Summary of Consolidated Financial Statements for the First Nine Months of Fiscal Year Ending December 31, 2023 [Japanese GAAP]

November 14, 2023

Company Name	**SymBio Pharmaceuticals Limited**	Listing: Tokyo Stock Exchange	
Securities Code	4582	URL: https://www.symbiopharma.com/	
Representative	Representative Director, President and Chief Executive Officer	Fuminori Yoshida	
Contact Person	Executive Corporate Officer and Chief Financial Officer	Takaaki Fukushima	TEL +81-3-5472-1125
Scheduled Date to File Quarterly Report	November 14, 2023	Date of Dividend Payment (plan)	–

Supplementary materials for the quarterly financial statements: Yes ・ [No]

Holding of quarterly earnings performance review: [Yes] ・ No

(Amounts of less than one million yen are rounded down.)

1. Business Results for the First Nine Months of FY 2023 (January 1, 2023 to September 30, 2023)

(1) Consolidated Operating Results (cumulative) (Percentages indicate year-on-year changes.)

	Net Sales		Operating Profit		Ordinary Profit		Profit attributable to owners of parent	
	Millions of yen	%	Millions of yen	%	Millions of yen	%	Millions of yen	%
Q3 FY 2023	4,421	(39.9)	(283)	–	(156)	–	(788)	–
Q3 FY 2022	7,355	–	1,588	–	1,843	–	1,555	–

(Note) Comprehensive income: Q3 FY 2023 (790) million yen [– %]
Q3 FY 2022 1,555 million yen [– %]

	Earnings per Share	Diluted Earnings per Share
	Yen	Yen
Q3 FY 2023	(19.89)	–
Q3 FY 2022	40.00	39.43

(Note) Diluted earnings per share is not stated due to recording of a net loss per share, despite the potential dilution of shares.

(2) Consolidated Financial Position

	Total Assets	Net Assets	Equity Ratio
	Millions of yen	Millions of yen	%
Q3 FY 2023 (as of September 30, 2023)	8,451	7.678	87.7
FY 2022 (as of December 31, 2022)	10,433	8,506	77.6

(Reference) Shareholders' equity: Q3 FY 2023 (as of September 30, 2023) 7,410 million yen
FY 2022 (as of December 31, 2022) 8,094 million yen

2. Dividends

	Annual Dividend per Share				
	1st Quarter	2nd Quarter	3rd Quarter	Fiscal Year End	Full Year
	Yen	Yen	Yen	Yen	Yen
FY 2022	–	0.00	–	0.00	0.00
FY 2023	–				
FY 2023 (Forecast)		0.00	–	0.00	0.00

(Note) Revision of dividend forecasts most recently announced: Yes ・ [No]

3. Earnings Forecasts for FY 2023 (January 1, 2023 to December 31, 2023)

(Percentages indicate year-on-year changes.)

	Net Sales		Operating Profit (Loss)		Ordinary Profit (Loss)		Profit (Loss) attributable to owners of parent		Earnings (Loss) per Share
	Millions of yen	%	Millions of yen	%	Millions of yen	%	Millions of yen	%	Yen
Full Year	5,603	(44.0)	(680)	–	(549)	–	(1,291)	–	(32.53)

(Note) Revision of earnings forecasts most recently announced: Yes ・ No

Notes:

(1) Changes in significant subsidiaries during the period: Yes ・ No

(Transfer of specified subsidiary accompanying a change in the scope of consolidation)

New: None

Removed: None

(2) Application of special accounting treatment in preparing the quarterly financial statements: Yes ・ No

(3) Changes in accounting policies, changes in accounting estimates and restatements after error corrections

(a) Changes in accounting policies due to revision of accounting standards: Yes ・ No

(b) Changes in accounting policies due to other reasons: Yes ・ No

(c) Changes in accounting estimates: Yes ・ No

(d) Restatements after error corrections: Yes ・ No

(4) Number of issued shares (common stock)

(i) Total number of issued shares at the end of the period (including treasury shares)	Q3 FY 2023	39,858,356 shares	FY 2022	39,603,606 shares
(ii) Total number of treasury shares at the end of the period	Q3 FY 2023	86,919 shares	FY 2022	85,268 shares
(iii) Average number of shares during the period (cumulative)	Q3 FY 2023	39,659,960 shares	Q3 FY 2022	38,893,556 shares

* Summary of the quarterly financial statements is not subject to quarterly reviews by certified public accountants or accounting corporations.

* Explanation regarding the appropriate use of earnings forecasts and other matters

All forecasts presented in this document, including earnings forecasts, are based on the information currently available to the Company and assumptions determined by the Company to be reasonable. Actual results may differ substantially from these forecasts due to various factors. Regarding the assumptions on which the Company's earnings forecasts are based and their usage, please refer to "1. Qualitative Information on Quarterly Financial Results (3) Explanation of consolidated earnings forecast and other forward-looking information" on Page 4 of the Appendix.

Appendix

Index

1. Qualitative Information on Quarterly Financial Results

(1) Business results

Progress of business of the Company and subsidiary ("the Group") for the first nine months of the fiscal year under review is as follows.

(i) Business results for the period under review

In December 2020, the Group began selling TREAKISYM® (generic name: bendamustine hydrochloride or bendamustine hydrochloride hydrate) through its own sales organization.

The Group has established a highly productive salesforce consisting of qualified medical representatives nationwide. As our medical representatives have expertise in hematology and are deployed nationally, they are capable of effectively addressing the local needs of institutions in each region in the country. To achieve nationwide distribution, we have entered into distribution agreements with Suzuken Co., Ltd. and Toho Pharmaceutical Co., Ltd. We are also working with S.D. Collabo Co., Ltd. and have established two logistics centers, one in eastern and one in western Japan.

In February 2022, the Group obtained approval for a partial change to the marketing authorization of the ready-to-dilute (RTD) liquid formulation of TREAKISYM® to add rapid infusion (RI) administration. The RTD formulation of TREAKISYM® is a liquid formulation that eliminates the need for manual reconstitution and significantly reduces preparation time. RI administration has the further advantage of reducing the infusion time to 10 minutes, benefiting both patients and healthcare providers. In addition, the reduction in infusion volume of RI means a lower volume of saline solution is used.

Conversion to the RI administration has proceeded smoothly, with nearly 90% of medical institutions switching to RI administration as of the end of September 2023.

Net sales of TREAKISYM® for Q3 totaled 4,421,104 thousand yen (-39.9% year on year). The primary factors for the year on year decrease are the continuing downward trend in prescriptions due to COVID-19 and seasonal influenza, and the impact of generic bendamustine products which entered the market in June 2022, and the temporary sales increase in the same period last year due to the increase in distribution inventory following the switch from freeze-dried (FD) to RTD.

Selling, general and administrative expenses totaled 3,759,453 thousand yen (-3.1% year on year). This amount includes research and development expenses of 1,823,633 thousand yen (+16.8% year on year).

As a result, operating loss was 283,204 thousand yen (versus an operating profit of 1,588,856 thousand yen for the same period in FY 2022) and ordinary profit was 156,382 thousand yen (versus 843,421 thousand yen for the same period in FY 2022). Loss attributable to owners of parent amounted to 788,713 thousand yen (versus a profit attributable to owners of parent of 1,555,746 thousand yen for the same period in FY 2022) due to the reversal of deferred tax assets of 568,382 thousand yen in income taxes-deferred.

In February 2022, generic bendamustine products were approved for manufacturing and marketing in Japan. Given the potential infringement of the patents related to TREAKISYM® in Japan which are exclusively licensed to the Company from Eagle Pharmaceuticals, Inc (head office: New Jersey, U.S.; hereinafter "Eagle"), the Company in coordination with Eagle notified four generic makers of potential patent infringement and, in December 2022, commenced litigation against the makers of the generic products, Towa Pharmaceutical Co., Ltd. (head office: Osaka) and Pfizer Japan Inc. (head office: Tokyo), seeking an injunction against the manufacture and sale of the products and compensation for damages arising from the infringement.

Segment information has been omitted as the Group operates within a single segment, which includes the research and development, manufacturing, and marketing of pharmaceutical drugs and other related activities.

(ii) Research and development activities

During the first nine months of FY 2023, we conducted the following research and development activities.

(a) Anticancer agents: SyB L-0501 (FD formulation), SyB L-1701 (RTD formulation), and SyB L-1702 (RI administration)
(generic name: bendamustine hydrochloride or bendamustine hydrochloride hydrate, trade name: TREAKISYM®)

For the RI administration, a partial change application was approved in February 2022, enabling the use of RI injection for all approved indications of the RTD formulation in-licensed from Eagle.

The Group continues to actively conduct further research on TREAKISYM®, such as ongoing joint research with Kyoto University, to explore new potential uses for the drug.

(b) Anticancer agents: SyB L-1101 (intravenous formulation) and SyB C-1101 (oral formulation) (generic name: rigosertib sodium)

For rigosertib in-licensed from Onconova Therapeutics, Inc. (head office: Pennsylvania, U.S.), the Group is collaborating with the University of Tokyo to conduct research to identify new potential indications or applications for the drug either alone or in combination with other existing drugs (including bendamustine).

(c) Antiviral drug: SyB V-1901 (intravenous formulation) (generic name: brincidofovir [BCV])

The Group obtained the exclusive license to brincidofovir from Chimerix Inc. (head office: North Carolina, U.S.; hereinafter "Chimerix") in September 2019. In September 2022, Emergent BioSolutions Inc. (head office: Maryland, U.S.) completed its acquisition of the exclusive worldwide rights to brincidofovir from Chimerix. The Group's exclusive worldwide license to develop, manufacture, and market BCV for all indications except orthopox virus infections (including smallpox and monkeypox) is not affected.

The Group is prioritizing global development of BCV (primarily in Japan, the U.S., and Europe), targeting disseminated adenovirus (AdV) infections occurring after hematopoietic stem cell transplantation. In March 2021, the Group filed an Investigational New Drug (IND) application with the FDA to conduct a Phase II clinical trial in patients (primarily pediatric but also adults) suffering from AdV infections. This development program was granted Fast Track designation by the FDA in April 2021. In May 2023, this study established human POC for BCV. Positive data demonstrating the efficacy of the study will be presented orally at the 65th Annual Meeting of the American Society of Hematology in December 2023.

In addition, the Group submitted a clinical trial notification for a Phase II study in patients infected with BK virus (BKV) infection after kidney transplantation to the Pharmaceuticals and Medical Devices Agency (PMDA) of Japan in May 2022 and filed another notification with the Therapeutic Goods Administration (TGA) of Australia in August 2022. BKV infection after kidney transplantation is a disease with serious consequences for the recipient, the donor, the medical practitioner, and society, due to the risk of impaired renal function and loss of the transplanted kidney (graft loss). The investigational drug was administered to the first subject in December 2022. Although the trial was planned to be completed in 2025, due to delays in the accumulation of cases, the protocol will be reviewed again with researchers.

In light of the drugs' broad effectiveness against double-stranded DNA (dsDNA) viruses, the Group is also collaborating with leading research institutions both in Japan and overseas to study BCV's potential use in the treatment of various other diseases.

Among dsDNA viruses, polyomaviruses are known to cause serious diseases through their infection. As existing antiviral drugs show little efficacy, there is a high level of medical need for the development of an effective treatment. In November 2022, the Group entered into Material Transfer Agreement with Penn State College of Medicine whereby the Group will provide BCV for use in a non-clinical study to evaluate the efficacy of BCV in a mouse model of polyomavirus infection.

In addition to having its strong antiviral effect, BCV also is expected to have an antitumor effect, and the Group is exploring BCV's potential in indications such as EBV-positive lymphoma, refractory brain tumors, and other cancers, through research collaborations with the National Cancer Centre Singapore (NCCS) and the University of California San Francisco (UCSF) Brain Tumor Center. In December 2022, the results of collaborative research with NCCS on the therapeutic efficacy of BCV in the treatment of NK/T-cell lymphoma, for which no effective treatment is currently available, were presented by Dr. Jason Chan at the 64th American Society of Hematology (ASH) Annual Meeting in New Orleans. Furthermore, in June 2023, the results of its research collaboration with NCCS on BCV were presented at the 17th International Conference on Malignant Lymphoma (ICML) in Lugano, Switzerland.

The Group is also investigating the use of BCV to treat multiple sclerosis, an intractable disease that has recently been shown to be associated with Epstein-Barr virus (EBV). In August 2022, the Company entered into a collaboration agreement with the National Institute of Neurological Disorders and Stroke (NINDS), part of the National Institutes of Health (NIH) in the U.S., for the transfer of materials to evaluate the antiviral effect of BCV in EBV. In March 2023, The Company has entered into a Cooperative Research and Development Agreement (CRADA) for BCV with NINDS and in October 2023, the results of the research were presented by Dr. Maria Chiara Monaco at the 9th Joint ECTRIMS-ACTRIMS Meeting in Milan, Italy.

The purpose of the CRADA is to verify the efficacy of BCV as an anti-viral therapeutic for EBV in the treatment of multiple sclerosis, and to obtain necessary data with a view to future clinical trials. In April 2023, the Company entered into a CRADA with the National Institute of Allergy and Infectious Diseases (NIAID), part of NIH in the U.S., to investigate the efficacy of BCV in

the treatment of EBV associated lymphoproliferative diseases.

Some dsDNA viruses, such as herpes simplex virus type 1 (HSV1) and varicella zoster virus (VZV), are directed against cranial nerve tissues. In recent years, research has advanced on the involvement of the reactivation of those viruses in various serious diseases of the nervous system, including Alzheimer's disease. In December 2022, the Group entered into a Sponsored Research Agreement with Tufts University to conduct research to evaluate the efficacy of BCV in a HSV infection model using a 3D (three-dimensional) brain model established by Tufts University.

(iii) Business outside Japan

In August 2023, the Group appointed Stephane Berthier, PharmD, as CEO and President of SymBio Pharma USA, Inc., and in September 2023, appointed Nkechi Azie, MD, to the Group management team as Global Chief Medical Officer (CMO) to further strengthen the Group's global development structure and make SymBio Pharma USA, Inc. the driving force for our international clinical trials as we move forward with our global development plan for BCV.

(iv) Licensing of new drug candidates

The Group continues to evaluate promising new drug candidates for in-licensing. Through these efforts, the Group aims to create medium-to long-term business value.

(2) Summary of financial position

Total consolidated assets as of September 31, 2023, stood at 8,451,704 thousand yen. Current assets totaled 7,894,019 thousand yen, mainly consisting of 6,114,867 thousand yen in cash and deposits, 924,782 thousand yen in accounts receivable-trade, and 333,785 thousand yen in merchandise and finished goods. Non-current assets were 557,684 thousand yen, mainly consisting of 176,346 thousand yen in deferred tax assets and 161,245 thousand yen in software.

Total liabilities were 773,057 thousand yen. Current liabilities totaled 769,152 thousand yen, mainly consisting of 587,892 thousand yen in accounts payable-other. Non-current liabilities were 3,905 thousand yen, consisting of 3,905 thousand yen in liabilities for retirement benefits.

Total net assets stood at 7,678,646 thousand yen. This includes 17,600,367 thousand yen in capital stock, 17,575,258 thousand yen in capital surplus, and 268,272 thousand yen in share acquisition rights.

As a result, the equity ratio was 87.7%.

(3) Explanation of consolidated earnings forecasts and other forward-looking information

For the forecast of financial results for the year ending December 31, 2023, although the impacts of generic bendamustine products were generally in line with our expectations, the overall bendamustine market has contracted due to a continuing decline in prescriptions and treatment delays due to seasonal influenza and COVID-19. As a result, the Company has revised its net sales forecast downward to 5,603 million yen, which is a reduction of 874 million yen compared to the previously announced forecast.

While continuing to prioritize R&D investment in ongoing global development of brincidofovir ("BCV"), the Company has reduced selling, general, and administrative expenses to mitigate adverse effects of the decrease in sales. As a result, the Company forecasts an operating loss of 680 million yen, which is a 349 million yen increase in loss compared to the previously announced forecast, and an ordinary loss of 549 million yen, which is a 330 million yen increase in loss compared to the previously announced forecast, despite foreign exchange valuation gains on foreign currency denominated assets.

Income tax adjustments have increased 642 million yen as a result of careful consideration of current business environment, future performance trends, and recoverability of deferred tax assets in the future. As a result, the net loss attributable to owners of the parent was revised downward to 1,291 million yen, a 921 million yen increase in loss than the previously announced forecast.

2. Quarterly Consolidated Financial Statements and Primary Notes

(1) Quarterly consolidated balance sheet

(Unit: thousands of yen)

	FY 2022 (as of December 31, 2022)	Q3 FY 2023 (as of September 30, 2023)
Assets		
Current assets		
Cash and deposits	6,282,554	6,114,867
Accounts receivable–trade	2,084,915	924,782
Merchandise and finished goods	293,757	333,785
Semi-finished goods	175,170	–
Prepaid expenses	209,886	178,679
Other	266,422	341,904
Total current assets	9,312,706	7,894,019
Non-current assets		
Property, plant and equipment		
Buildings, net	40,670	212
Tools, furniture and fixtures, net	28,339	19,403
Construction in progress	–	6,000
Total property, plant and equipment	69,009	25,616
Intangible assets		
Software	222,204	161,245
Software in progress	–	2,200
Total intangible assets	222,204	163,445
Investments and other assets		
Deferred tax assets	744,728	176,346
Leasehold and guarantee deposits	84,698	192,276
Total investments and other assets	829,427	368,623
Total non-current assets	1,120,641	557,684
Total assets	10,433,347	8,451,704
Liabilities		
Current liabilities		
Accounts payable–trade	46,633	–
Accounts payable–other	1,163,721	587,892
Income taxes payable	401,066	25,176
Provision for product changeover	16,331	–
Other	296,118	98,681
Total current liabilities	1,923,870	769,152
Non-current liabilities		
Liabilities for retirement benefits	3,385	3,905
Total non-current liabilities	3,385	3.905
Total liabilities	1,927,255	773,057

(Unit: thousands of yen)

	FY 2022 (as of December 31, 2022)	Q3 FY 2023 (as of September 30, 2023)
Net assets		
Shareholders' equity		
Share capital	17,548,459	17,600,367
Capital surplus	17,523,357	17,575,258
Retained earnings	(28,889,486)	(27,678,199)
Treasury shares	(88,154)	(88,898)
Total shareholders' equity	8,094,176	7,408,527
Accumulated other comprehensive income		
Foreign currency translation adjustment	243	1,846
Total accumulated other comprehensive income	243	1,846
Share acquisition rights	411,672	268,272
Total net assets	8,506,092	7,678,646
Total liabilities and net assets	10,433,347	8,451,704

(2) Quarterly consolidated statement of income and consolidated statement of comprehensive income

Quarterly consolidated statement of income for the first nine months of FY 2023

(Unit: thousands of yen)

	Q3 FY 2022 (from January 1, 2022 to September 30, 2022)	Q3 FY 2023 (from January 1, 2023 to September 30, 2023)
Net sales	7,355,507	4,421,104
Cost of sales	1,888,901	944,855
Gross profit	5,466,606	3,476,249
Selling, general and administrative expenses	3,877,749	3,759,453
Operating profit (loss)	1,588,856	(283,204)
Non-operating income		
Interest income	95	267
Foreign exchange gains	345,287	167,560
Other	2,925	3,711
Total non-operating income	348,309	171,538
Non-operating expenses		
Commission expenses	47,590	10,346
Share issuance costs	45,617	3,278
Provision for office relocation expenses	–	25,176
loss on retirement of fixed assets	536	5,915
Total non-operating expenses	93,744	44,716
Ordinary profit	1,843,421	(156,382)
Extraordinary income		
Gain on reversal of share acquisition rights	106,401	101,333
Total extraordinary income	106,401	101,333
Extraordinary loss		
Impairment loss	–	75,543
Total extraordinary loss	–	75,543
Profit before income taxes	1,949,823	(130,592)
Income taxes - current	250,928	89,736
Income taxes - deferred	143,147	568,382
Total income taxes	394,076	658,120
Profit (loss)	1,555,746	(788,713)
Profit attributable to non-controlling interests	–	–
Profit (loss) attributable to owners of parent	1,555,746	(788,713)

Quarterly consolidated statement of comprehensive income for the first nine months of FY 2023

(Unit: thousands of yen)

	Q3 FY 2022 (from January 1, 2022 to September 30, 2022)	Q3 FY 2023 (from January 1, 2023 to September 30, 2023)
Profit	1,555,746	(788,713)
Accumulated other comprehensive income		
Foreign currency translation adjustment	(21)	(1,603)
Total other comprehensive income	(21)	(1,603)
Comprehensive income	1,555,325	(790,316)
Comprehensive income attributable to		
Comprehensive income attributable to owners of parent	1,555,325	(790,316)
Comprehensive income attributable to non-controlling interests	–	–

(3) Notes to quarterly consolidated financial statements

(Notes to going concern assumptions)

None to be reported.

(Notes in case of significant changes to shareholders' equity)

In the first nine months of FY 2023, the Company issued new shares due to the exercise of some of share acquisition rights pertaining to the 33rd, 43rd, 44th, 48th, 49th, 52nd, and 53rd warrants. As a result, share capital increased by 51,907 thousand yen and capital surplus increased by 51,907 thousand yen. The total value of treasury shares increased 772 thousand yen as a result of share repurchases.

The disposal of treasury shares in response to the request to sell shares by shareholders of less-than-one unit of shares led to a decrease of 28 thousand yen in the total value of treasury shares and a decrease of 6 thousand yen in other capital surplus.

As a result, as of September 30, 2023, consolidated share capital was 17,600,367 thousand yen, capital surplus was 17,575,258 thousand yen, and the total value of treasury shares was 88,898 thousand yen.

(Accounting policy changes)

The Company has applied the "Accounting Standard for Fair Value Measurement" (ASBJ Statement No. 31; June 17, 2021; hereinafter "Fair Value Measurement Standard") from the beginning of the first quarter of FY 2023.

In applying the Fair Value Measurement Standard, the Company has followed the transitional treatment prescribed in the transitional measures provided for in paragraph 27-2 of the Implementation Guidance on Accounting Standard for Fair Value Measurement and will apply the new accounting standard prescribed by the Fair Value Measurement Standard, prospectively.

The adoption of this accounting standard has no effect on the quarterly consolidated financial statements.

(Significant subsequent events)

(Execution of agreement establishing share issuance program and issuance of new shares by way of third-party allotment)

On October 6, 2023 (the "Initial Press Release"), the Company announced that the Company's Board of Directors, at a meeting held on the same date, had resolved to enter into an agreement with EVO FUND (the "Allottee") to set up an equity issue program (the "Agreement to Set up an Equity Issue Program"), and based on the equity issue program established under the Agreement to Set up an Equity Issue Program (the "Program"), to issue new shares in five tranches (shares issued to the Allottee, whether individually or collectively, under the Program are referred to as the "Shares").

The Company is authorized to issue up to a total of 6,000,000 ordinary shares by way of third-party allotment to the allottees in the period from 25 October 2023 to 3 April 2024, with ordinary shares to be issued by way of a total of five allotments, from the first to the fifth allotment.

As at the date of submission, the new shares to be issued by way of third-party allotment are as follows.

(1st allotment) *Note 1

Payment was completed on November 10, 2023

1	Class and Numbers Shares Offered	1,200,000 common shares
2	Issue Price	316 yen per share
3	Capital inclusion amount	158 yen per share
4	Total Issue Price	379,200,000 yen
5	Increases in Capital Stock and Legal Capital Surplus	189,600,000 yen
6	Deadline for Application	November 10, 2023
7	Due Date of Payment	November 10, 2023
8	Allottee	EVO FUND

9	Specific uses	(1) Development funds for antiviral drug brincidofovir (direct expenses) (2) Development funds for antiviral drug brincidofovir (indirect expenses) (3) Investment in new in-licensing and M&A for the purpose of securing long-term growth opportunities.

(2nd allotment) *Note 1

1	Class and Numbers Shares Offered	1,200,000 common shares
2	Issue Price	To be determined *Note 2
3	Capital inclusion amount	The amount to be contributed to capital stock shall be half the upper limit of an increase in capital stock under Article 14, Paragraph 1, of the Rules of Corporate Accounting (with any fractional amounts less than one yen resulting from such calculation rounded up). The increase in the legal surplus shall be the upper limit of an increase in capital stock less the amount of the increase in capital stock.
4	Total Issue Price	To be determined.
5	Increases in Capital Stock and Legal Capital Surplus	To be determined.
6	Allotment resolution date	December 4, 2023 *Note 3
7	Deadline for Application	December 20, 2023
8	Due Date of Payment	December 20, 2023 *Note 3
9	Allottee	EVO FUND
10	Specific uses	(1) Development funds for antiviral drug brincidofovir (direct expenses) (2) Development funds for antiviral drug brincidofovir (indirect expenses) (3) Investment in new in-licensing and M&A for the purpose of securing long-term growth opportunities.

(3rd allotment) *Note 1

1	Class and Numbers Shares Offered	1,200,000 common shares
2	Issue Price	To be determined *Note 2
3	Capital inclusion amount	The amount to be contributed to capital stock shall be half the upper limit of an increase in capital stock under Article 14, Paragraph 1, of the Rules of Corporate Accounting (with any fractional amounts less than one yen resulting from such calculation rounded up). The increase in the legal surplus shall be the upper limit of an increase in capital stock less the amount of the increase in capital stock.

4	Total Issue Price	To be determined.
5	Increases in Capital Stock and Legal Capital Surplus	To be determined.
6	Allotment resolution date	January 22, 2024 *Note 3
7	Deadline for Application	February 7, 2024
8	Due Date of Payment	February 7, 2024 *Note 3
9	Allottee	EVO FUND
10	Specific uses	(1) Development funds for antiviral drug brincidofovir (direct expenses) (2) Development funds for antiviral drug brincidofovir (indirect expenses) (3) Investment in new in-licensing and M&A for the purpose of securing long-term growth opportunities.

(4th allotment) *Note 1

1	Class and Numbers Shares Offered	1,200,000 common shares
2	Issue Price	To be determined *Note 2
3	Capital inclusion amount	The amount to be contributed to capital stock shall be half the upper limit of an increase in capital stock under Article 14, Paragraph 1, of the Rules of Corporate Accounting (with any fractional amounts less than one yen resulting from such calculation rounded up). The increase in the legal surplus shall be the upper limit of an increase in capital stock less the amount of the increase in capital stock.
4	Total Issue Price	To be determined.
5	Increases in Capital Stock and Legal Capital Surplus	To be determined.
6	Allotment resolution date	February 29, 2024 *Note 3
7	Deadline for Application	March 18, 2024
8	Due Date of Payment	March 18, 2024 *Note 3
9	Allottee	EVO FUND
10	Specific uses	(1) Development funds for antiviral drug brincidofovir (direct expenses (2) Development funds for antiviral drug brincidofovir (indirect expenses) (3) Investment in new in-licensing and M&A for the purpose of securing long-term growth opportunities.

(5th allotment) *Note 1

1	Class and Numbers Shares Offered	1,200,000 common shares
2	Issue Price	To be determined

3	Capital inclusion amount	The amount to be contributed to capital stock shall be half the upper limit of an increase in capital stock under Article 14, Paragraph 1, of the Rules of Corporate Accounting (with any fractional amounts less than one yen resulting from such calculation rounded up). The increase in the legal surplus shall be the upper limit of an increase in capital stock less the amount of the increase in capital stock.
4	Total Issue Price	To be determined.
5	Increases in Capital Stock and Legal Capital Surplus	To be determined.
6	Allotment resolution date	April 3, 2023 *Note 3
7	Deadline for Application	April 19, 2024
8	Due Date of Payment	April 19, 2024 *Note 3
9	Allottee	EVO FUND
10	Specific uses	(1) Development funds for antiviral drug brincidofovir (direct expenses (2) Development funds for antiviral drug brincidofovir (indirect expenses) (3) Investment in new in-licensing and M&A for the purpose of securing long-term growth opportunities.

*Note 1. The number of shares for each of the 2nd through 5th allotments will range from 1,200,000 shares to 2,500,000 shares, and the total will not exceed the 6,000,000 shares stipulated for issuance under the Program. The actual number will be determined by the Allottee notifying the Company prior to the date of the resolution by the Board of Directors for each allotment (the "Allotment Resolution Date").

*Note 2.The issue price for each allotment will be the amount equal to the simple average of the closing price of common shares of the Company announced by the Tokyo Stock Exchange, Inc. (the "TSE") during the 10 trading days up to and including the day immediately preceding the Allotment Resolution Date (rounded off to the first decimal place). (However, if there is no closing price for any of the 10 trading days, the Allotee may decide whether to include such a day in the calculation of the issue price.)

*Note 3. The Allotment Resolution Date and the due date of payment may be changed, if agreed upon by the Company and the Allottee. If such changes occur, the Company will withdraw the securities registration statement allotment and submit a new securities registration statement.